Esam Elshimi is working at Menoufia University, Egypt. He is the recipient of numerous awards for his research works in related fields. His research interests reflect in his wide range of publications in various national and international journals.
Background: Matrix metalloproteinase-12(MMP-12) is involved in tumor invasiveness and metastasis and significantly over-expressed in tissues of HCC.
Aim: Aim of this study was to investigate the diagnostic and prognostic value of serum mRNA MMP-12 over expression in human HCC on top of HCV related cirrhosis.
Subjects & Methods: From January 2016 to June 2016, 50 patients with chronic HCV related cirrhosis and HCC, 50 patients with HCV related cirrhosis compared to 50 healthy persons as a control group. They were selected from National Liver Disease–Menoufia University; all patients were subjected to tri-phasic CT abdomen when indicated, liver profile, AFP and molecular characterization of metalloproteinase-12 expression by molecular biology techniques.
Results: There were statistically significant differences between HCC and cirrhotic patients versus control group regarding (CBC parameters and liver profile), (p-value<0.01), while there were no differences between all groups regarding creatinine (p-value>0.05). There was a statistically significant difference between HCC patients and other groups regarding mRNA-MMP12 (p-value<0.01), sensitivity 72.0%, specificity 60.0%, AUC0.68, accuracy 70.9%, P value<0.01, mRNA-MMP12 and/or AFP had sensitivity of 84.0%, specificity 60.0%, PPV of 51.2, NPP 88.2%. Accuracy of mRNA-MMP12 and/or AFP=68.0%. The sensitivity of mRNA-MMP12 and AFP= 58.0 %, specificity 78.0%, PPV 56.9%, NPV 78.8% and accuracy 71.3%.
Conclusion: mRNA-MMP12 is a good sensitive, bad specific but accurate in diagnosing HCC. Adding serum mRNA-MMP12 to AFP improves early diagnosis and hence, better prognosis.